There has been a lot of discussion about a number of “on the horizon” drugs that are designed to aggressively treat advanced prostate cancer, including MDV3100. MDV3100 is supposed to act as a “super” antiandrogen (Casodex is the currently most used antiandrogen in the treatment of advanced prostate cancer).
You may qualify to participate in this phase III trial called PREVAIL if you meet the following criteria:
1- If you have advanced prostate cancer (spread outside the prostate gland).
2- If you have become castrate resistant (your prostate cancer is no longer being controlled
by hormone therapy (ADT).
3- Your prostate cancer does not cause you any pain or just mild pain.
4- You have not yet had any chemotherapy (taxotere or Jevtana)
To find out more about this trial go to (in the United States and Canada)go to:
or call: 855-977-3825
If you live outside of the United States or Canada you should submit a request for more information at information.
If you do live outside the United States or Canada you still may be able to participate in the PREVAIL trial if you meet all the above requirements and are able to travel to one of these
clinical trial locations.
Joel T. Nowak, M.A., M.S.W.